Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Ani Pharmaceuticals (ANIP) over the last 16 years, with Q3 2025 value amounting to $1.19.

  • Ani Pharmaceuticals' EPS (Basic) rose 19370.08% to $1.19 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.71, marking a year-over-year increase of 41090.91%. This contributed to the annual value of -$1.04 for FY2024, which is 20944.08% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' EPS (Basic) stood at $1.19, which was up 19370.08% from $0.37 recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' EPS (Basic) registered a high of $1.19 during Q3 2025, and its lowest value of -$1.93 during Q4 2021.
  • For the 5-year period, Ani Pharmaceuticals' EPS (Basic) averaged around -$0.24, with its median value being -$0.14 (2024).
  • In the last 5 years, Ani Pharmaceuticals' EPS (Basic) plummeted by 1892108.64% in 2022 and then skyrocketed by 130000.0% in 2024.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' EPS (Basic) stood at -$1.93 in 2021, then surged by 84.98% to -$0.29 in 2022, then soared by 114.35% to $0.04 in 2023, then crashed by 1428.94% to -$0.55 in 2024, then surged by 315.21% to $1.19 in 2025.
  • Its EPS (Basic) stands at $1.19 for Q3 2025, versus $0.37 for Q2 2025 and $0.7 for Q1 2025.